Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Janssen Launches RSV Vaccine to Treat Older Patients

An investigational prophylactic vaccine has been launched by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) for the prevention of respiratory syncytial virus (RSV)-mediated lower respiratory tract disease.

The Company’s adenovector platform (AdVac) is utilised by the prophylactic RSV senior vaccine to deliver the gene encoding for the fusion protein of RSV virus as an antigen.  

Clinical trials held by Janssen demonstrated substantial improvement compared to the current standard of care.

Currently, the vaccine is in a Phase IIb proof of concept study to investigate the safety and efficacy of the treatment in adults aged 65 years and older.

The US Food and Drug Administration (FDA) has granted its Breakthrough Therapy Designation for the RSV vaccine.

RSV is a highly prevalent and contagious respiratory infection.

It is the most common cause of bronchitis and pneumonia and usually manifests with cold-like symptoms making it difficult to discern from influenza or various respiratory infections.

The medication is intended for adults aged 60 years or older.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024